Overview
flowchart TD
PSP["PSP"] -->|"associated with"| Alzheimer["Alzheimer"]
PSP["PSP"] -->|"associated with"| Als["Als"]
PSP["PSP"] -->|"associated with"| Alzheimer_s_disease["Alzheimer's disease"]
PSP["PSP"] -->|"expressed in"| neurons["neurons"]
PSP["PSP"] -->|"downregulates"| SV2A["SV2A"]
PSP["PSP"] -->|"targets"| tauopathy["tauopathy"]
PSP["PSP"] -->|"participates in"| unfolded_protein_response["unfolded protein response"]
PSP["PSP"] -->|"regulates"| STX6["STX6"]
PSP["PSP"] -->|"associated with"| frontotemporal_dementia["frontotemporal dementia"]
PSP["PSP"] -->|"participates in"| oxidative_stress_response["oxidative stress response"]
PSP["PSP"] -->|"associated with"| Parkinson_s_disease["Parkinson's disease"]
PSP["PSP"] -->|"regulates"| Parkinson_s_disease["Parkinson's disease"]
PSP["PSP"] -->|"associated with"| tauopathy["tauopathy"]
PSP["PSP"] -->|"biomarker for"| Ms["Ms"]
style PSP fill:#4fc3f7,stroke:#333,color:#000
TPN-101 is an oral small molecule tau metabolism modulator being developed for the treatment of Progressive Supranuclear Palsy (PSP). This Phase 2a study represents a critical milestone in the development of disease-modifying therapies for PSP, addressing the urgent unmet need for treatments that can slow or halt disease progression in this devastating neurodegenerative disorder["@nct"].
Trial Details
...Overview
Mermaid diagram (expand to render)
TPN-101 is an oral small molecule tau metabolism modulator being developed for the treatment of Progressive Supranuclear Palsy (PSP). This Phase 2a study represents a critical milestone in the development of disease-modifying therapies for PSP, addressing the urgent unmet need for treatments that can slow or halt disease progression in this devastating neurodegenerative disorder["@nct"].
Trial Details
| Field | Value |
|-------|-------|
| NCT ID | NCT04993768 |
| Status | Phase 2a (Completed) |
| Phase | Phase 2a |
| Sponsor | Translational Research Industries (TRI) |
| Study Design | Open-label, preliminary safety and tolerability |
| Intervention | TPN-101 oral administration |
| Enrollment | Approximately 40 participants |
| Condition | Progressive Supranuclear Palsy |
Mechanism of Action
Tau Pathology in PSP
TPN-101 targets the core pathological mechanism in PSP: the abnormal metabolism and aggregation of tau protein. PSP is classified as a primary 4R-tauopathy[@irwin2013].
The therapeutic approach reflects the growing understanding of tau propagation as a prion-like process[@sweeney2017]:
Tau misfolding: Pathological tau adopts a beta-sheet rich conformation
Oligomer formation: Small oligomeric tau species are believed to be the most toxic
Fibril aggregation: Hyperphosphorylated tau assembles into paired helical filamentsTPN-101's Proposed Mechanism
- Modulate tau protein metabolism: Interfere with abnormal tau processing
- Reduce pathological tau species: Lower levels of hyperphosphorylated tau
- Protect neuronal function: Support microtubule stability
Scientific Rationale
Tau as a Therapeutic Target
The tau hypothesis in PSP is strongly supported by multiple lines of evidence[@boxer2020]:
Genetic evidence: [MAPT](/genes/mapt) mutations cause familial PSP-like syndromes
Neuropathology: 4R-tau filaments are the defining pathological lesion in PSP brain
Biomarker studies: CSF tau species correlate with disease severity
Imaging: Tau PET signals correlate with clinical phenotype[@vignoud2021]Comparison with Other Tau-Targeted Approaches
| Approach | Examples | Advantages |
|----------|----------|------------|
| Small Molecules | TPN-101, LMTM | Oral bioavailability |
| Active Immunization | AADvac1 | Long-lasting immunity |
| Passive Immunization | ABBV-8E12, E2814 | High specificity |
PSP Disease Background
Clinical Features
PSP manifests with multiple core symptoms[@stamelou2019]:
- Vertical supranuclear gaze palsy (VSGP): Difficulty with downward eye movements
- Postural instability: Frequent falls, typically backward
- Parkinsonism: Bradykinesia, rigidity (axial > limbs)
- Cognitive dysfunction: Frontal executive impairment
- Dysphagia: Swallowing difficulties leading to aspiration risk
Clinical Subtypes
| Subtype | Prevalence | Key Features |
|---------|------------|--------------|
| Richardson's syndrome (PSP-RS) | ~50% | Classic presentation |
| PSP-parkinsonism (PSP-P) | ~25% | Better levodopa response |
| PSP-corticobasal syndrome (PSP-CBS) | ~10% | Cortical sensory loss |
| Pure akinesia with gait freezing (PAGF) | ~5% | Predominant gait freezing |
Neuropathology
The hallmark lesion is neurofibrillary tangles composed of hyperphosphorylated 4R-tau. Key regions affected include[@lees2017]:
- Substantia nigra pars compacta: Dopaminergic neuron loss
- Globus pallidus: Tau accumulation
- Brainstem nuclei: Colliculi, oculomotor nucleus
Current PSP Treatment Landscape
Symptomatic Treatments
Current management is primarily supportive:
- Levodopa: Modest benefit in some PSP-P patients
- Botulinum toxin: For dystonia
- Physical therapy: Gait and balance training
- Speech therapy: For dysphagia management
Disease-Modifying Therapies in Development
- Tau Aggregation Inhibitors: Tolfenamic acid, Lithium
- Immunotherapies: Bepranemab, ABBV-8E12
- Neuroprotective Agents: CoQ10, TPN-101
Clinical Trial Design Considerations
Challenges in PSP Trials
PSP clinical trials face unique challenges[@litvan2011]:
Diagnostic uncertainty: Overlaps with PD, CBS, MSA
Heterogeneous progression: Subtypes progress at different rates
Small patient population: Rare disease limits enrollment
Rapid progression: High dropout ratesOutcome Measures
- PSP Rating Scale (PSPRS): 36-item disease severity scale
- MDS-UPDRS: Motor and total scores
- Clinical Dementia Rating (CDR): Cognitive assessment
Significance of TPN-101
Novel mechanism: Targets tau metabolism directly
Oral delivery: More convenient than injectable biologics
Disease-modifying: Targets core pathology
4R-tau specificity: Direct approach to PSP pathologyRegulatory Considerations
The FDA has granted orphan drug designation to several PSP therapies, providing:
- 7 years of market exclusivity upon approval
- Tax credits for clinical trials
- Priority review for serious conditions
Tau Biology and Therapeutic Targets
Tau Protein Structure and Function
The tau protein is encoded by the [MAPT](/genes/mapt) gene on chromosome 17q21 and plays critical roles in neuronal physiology:
Isoforms: Alternative splicing produces six tau isoforms in the adult human brain:
- 0N, 1N, 2N (based on N-terminal inserts)
- 3R, 4R (based on microtubule-binding repeat number)
Functions:
- Microtubule stabilization and assembly
- Axonal transport facilitation
- Neuronal plasticity regulation
- DNA protection
Post-Translational Modifications:
- Phosphorylation at >45 sites
- Acetylation, methylation, ubiquitination
- Truncation and citrullination
- O-GlcNAcylation
Tau Aggregation in PSP
PSP is characterized by 4R-tau filament accumulation:
Neurofibrillary Tangles (NFTs):
- Paired helical filaments (PHF) and straight filaments
- Composed of hyperphosphorylated tau
- Distinct progression pattern from AD
Cellular Distribution:
- Neuronal tangles and threads
- Glial tau pathology (tufted astrocytes, coiled bodies)
- Neuropil threads in affected regions
Spreading Mechanism:
- Templated seeding (prion-like)
- Exosomal transport
- Trans-synaptic transmission
See Also
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
- [Tau Protein](/proteins/tau)
- [Tau Therapeutics Pipeline](/therapeutics/tau-therapeutics-pipeline)
- [MAPT Gene](/genes/mapt)
- [4R-Tauopathies](/mechanisms/4r-tauopathies)
External Links
- [NCT04993768 on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04993768)
- [CurePSP Foundation](https://curepsp.org/)
- [Movement Disorder Society](https://www.movementdisorders.org/)
References
[NCT04993768 - TPN-101 in PSP](https://clinicaltrials.gov/study/NCT04993768)[@nct]
[Höglinger GU et al., Clinical diagnosis of progressive supranuclear palsy: The MDSPSP criteria (2017)](https://pubmed.ncbi.nlm.nih.gov/28692957/)[@hoglinger2017]
[Boxer AL et al., Tau-targeted therapies for Alzheimer disease and tauopathies (2020)](https://pubmed.ncbi.nlm.nih.gov/32755574/)[@boxer2020]
[Vignoud G et al., Tau imaging in progressive supranuclear palsy (2021)](https://pubmed.ncbi.nlm.nih.gov/34152279/)[@vignoud2021]
[Stamelou M et al., Progressive supranuclear palsy: Distinctive features and neuroimaging findings (2019)](https://pubmed.ncbi.nlm.nih.gov/30648792/)[@stamelou2019]
[Lees AJ et al., Neurobiology and pathophysiology of progressive supranuclear palsy (2017)](https://pubmed.ncbi.nlm.nih.gov/28240337/)[@lees2017]
[Litvan I et al., Planning and designing clinical trials for progressive supranuclear palsy (2011)](https://pubmed.ncbi.nlm.nih.gov/21328041/)[@litvan2011]
[Respondek G et al., The phenotypic spectrum of progressive supranuclear palsy (2020)](https://pubmed.ncbi.nlm.nih.gov/24072416/)[@responder2020]
[Irwin DJ et al., Tau physiology and pathobiology in tauopathies (2013)](https://pubmed.ncbi.nlm.nih.gov/23447490/)[@irwin2013]
[Sweeney P et al., Modeling Alzheimer's disease and the prion-like spread of tau pathology (2017)](https://pubmed.ncbi.nlm.nih.gov/28663424/)[@sweeney2017]From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: AQP4
- [Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: P2RY12
- [Sphingolipid Metabolism Reprogramming](/hypothesis/h-6657f7cd) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: CERS2
- [Complement C1q Subtype Switching](/hypothesis/h-5a55aabc) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: C1QA
- [Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: HSPG2
- [Ephrin-B2/EphB4 Axis Manipulation](/hypothesis/h-e6437136) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: EPHB4
- [Netrin-1 Gradient Restoration](/hypothesis/h-05b8894a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: NTN1
Related Analyses:
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving TPN-101 for Progressive Supranuclear Palsy discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)